Menu
Back to Journals » Drug Design, Development and Therapy » Volume 4
Original Research
A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 19,176 | Dovepress* | 17,328+ | 2,084 | 19,412 | |
| PubMed Central* | 1,848 | 680 | 2,528 | ||
| Totals | 19,176 | 2,764 | 21,940 | ||
|
*Since 15 November 2010 +Since July 2016 |
|||||
| Total mentioned | Delicious | Others | |||
|---|---|---|---|---|---|
| 8 | 0 | 0 | 0 | 0 | 8 |
View citations on PubMed Central and Google Scholar